2025-09-28 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the data you provided.

## TMDX: TransMedics Group Inc. Analysis

TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation systems for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 178.05%
*   **VOO Cumulative Return:** 55.02%
*   **Current Divergence (TMDX - VOO):** -27.9
*   **Relative Divergence:** 23.7

**Analysis:**

TMDX has significantly outperformed the S&P 500 (VOO) over the analyzed period. The relative divergence of 23.7 suggests that TMDX's performance, while still positive in terms of cumulative return, is currently positioned in the lower range of its historical divergence from the S&P 500. However, it's important to note that the divergence is negative (-27.9), indicating that the gap between TMDX and VOO returns has narrowed recently.

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2019-2021  | -13.0%  | 83.5%   | -41.0%  | -0.0   | 0.7    |
| 2020-2022  | 101.0%  | 83.5%   | 87.0%   | 0.0   | 2.1    |
| 2021-2023  | 66.0%   | 80.5%   | 48.0%   | 0.3   | 2.7    |
| 2022-2024  | 121.0%  | 85.4%   | 108.0%  | 0.3   | 2.1    |
| 2023-2025  | 93.0%   | 85.4%   | 58.0%   | 0.2   | 3.9    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) is highly variable, with a negative value from 2019-2021 and strong positive values in subsequent periods, indicating volatile growth.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, reflecting significant risk or volatility.
*   **Alpha:** The Alpha values are generally very high, indicating that TMDX has performed well relative to its risk (Beta).
*   **Beta:** The Beta values are very low.
*   **Market Cap:** The Market Cap has increased from 0.7B to 3.9B.

### 2. Recent Price Action

*   **Current Price:** 113.87
*   **Previous Close:** 113.90
*   **Change:** -0.03
*   **5-day Moving Average:** 117.45
*   **20-day Moving Average:** 113.7958
*   **60-day Moving Average:** 116.7124

**Analysis:**

The current price shows a slight decrease compared to the previous close. The 5-day moving average is above the 20-day and 60-day moving averages, which could indicate a short-term downtrend. The price is below both the 5-day and 60-day averages, suggesting some recent weakness.

### 3. Indicators & Signals

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 60.83
*   **PPO:** 0.17
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (111 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** -2.3 (Short-term decline)
*   **Expected Return:** 22.5% (Long-term, vs. S&P 500)

**Analysis:**

The MRI suggests that the market conditions are favorable for investment in TMDX. The RSI is near the 60 level, indicating that it is at nearly overbought levels, but the PPO is near zero. The hybrid signal recommends a full investment. The recent decrease in relative divergence indicates that TMDX has been underperforming the S&P 500 in the short term. The expected return of 22.5% suggests a potentially significant long-term outperformance relative to the S&P 500, but this is an estimate. The minute price change doesn't indicate a significant market reaction.

### 4. Recent News & Significant Events

*   **Positive Coverage:** Multiple articles highlight TMDX as a strong growth stock and potentially undervalued.
*   **Mercedes-Benz Partnership:** The collaboration with Mercedes-Benz for organ transport is a significant development, particularly in Italy.
*   **Bull Case Theory:** Articles discuss the positive outlook for TMDX.

**Analysis:**

The recent news is overwhelmingly positive, with several articles highlighting the company's growth potential and the strategic partnership with Mercedes-Benz. This positive news flow could be a catalyst for further growth.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~1.82)
*   **Target Price:** $140.67 (Average), $170.00 (High), $114.00 (Low)

**Analysis:**

Analysts generally have a positive outlook on TMDX, with a consensus rating of "Buy". The average target price of $140.67 suggests potential upside from the current price, while the low target price is close to the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.70 | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:**

TMDX has consistently beaten EPS estimates in recent quarters except for 2025-02-27 and 2024-10-28. This suggests strong financial performance and effective management.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-06-30 | $0.32B   | 10.97% |
| 2025-03-31 | $0.27B   | 9.64%  |
| 2024-12-31 | $0.23B   | 3.00%  |
| 2024-09-30 | $0.21B   | 2.01%  |
| 2024-06-30 | $0.19B   | 6.42%  |

**Analysis:**

*   **Revenue:** Revenue has shown consistent growth over the past five quarters.
*   **Profit Margin:** Profit margins are very high and stable, indicating strong pricing power and efficient operations.
*   **Equity:** Equity has been increasing, suggesting strong financial health.
*   **ROE:** ROE has increased and decreased recently, indicating greater efficency in the last 2 quarters.

### 7. Overall Assessment

TransMedics Group Inc. (TMDX) presents a compelling investment case based on the provided data. The company has significantly outperformed the S&P 500 in the past, and analysts have a positive outlook for the stock. Recent news is positive, highlighting growth potential and strategic partnerships. The company has been consistenly beating EPS estimates in recent quarters.

However, it's important to acknowledge the inherent risks, including the recent short-term underperformance relative to the S&P 500. The high MDD values also suggest significant volatility.

**Recommendation:**

Based on the information, TMDX appears to be a potentially attractive investment, particularly for investors with a long-term focus. The company's strong growth prospects, positive analyst ratings, and innovative technology make it a compelling opportunity. However, investors should be aware of the risks associated with the stock, including the recent short-term underperformance and high volatility.
